Xofigo (Radium-223-dichloride) - Important Safety Information from Bayer AG as approved by the HPRA (March 2018)

Notice type: 3rd Party Publications

Date: 20/03/2018

Important Safety Information communication from Bayer AG: Xofigo (Radium-223-dichloride) - contraindicated in combination with abiraterone acetate and prednisolone/prednisone

Important Safety Information - Xofigo (Radium-223-dichloride) (March 2018)